Statistics
Publications
10
Citations
721
H-Index
10
Active since
2017
Xinwei Kuang is an author at Xiangya Hospital Central South University specializing in checkpoint inhibitor therapy, immune checkpoint inhibitors, and cancer immunotherapy.
Publications per year
2017–2025
10
10
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis
Hong Liu, Xinwei Kuang, Yongchang Zhang et al. · Cancer Cell · 2020 · 259 citations · Full text
Medicine, Cancer Biology, Oncology +12
Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1
Youqiong Ye, Xinwei Kuang, Zuozhong Xie et al. · Genome Medicine · 2020 · 157 citations · Full text
Medicine, Immunology, Oncology +17
Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma
Long Liang, Xinwei Kuang, Yi He et al. · Nature Genetics · 2025 · 72 citations · Full text
Medicine, Oncology, Pharmacology +17
The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1
Hui Li, Xinwei Kuang, Long Liang et al. · Advanced Science · 2020 · 61 citations · Full text
Profiling of immune features to predict immunotherapy efficacy
Youqiong Ye, Yongchang Zhang, Nong Yang et al. · The Innovation · 2021 · 43 citations · Full text
Life Sciences, Immunology, Oncology +17
1–5 of 10